Issue 4/2012
Content (30 Articles)
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial
David A. Reardon, Patrick Y. Wen, W. K. Alfred Yung, Lori Berk, Narayana Narasimhan, Christopher D. Turner, Timothy Clackson, Victor M. Rivera, Michael A. Vogelbaum
Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer
Yoshinori Makino, Noboru Yamamoto, Hitoshi Sato, Reiko Ando, Yasushi Goto, Chiharu Tanai, Hajime Asahina, Hiroshi Nokihara, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Erika Sugiyama, Nobuaki Yokote, Tomohide Tamura, Hiroshi Yamamoto
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
M. Campone, N. Isambert, E. Bourbouloux, H. Roché, J. Bonneterre, G. Milano, P. Fumoleau
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
Emma K. Hansson, Lena E. Friberg
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
H. Murakami, T. Tamura, T. Takahashi, H. Nokihara, T. Naito, Y. Nakamura, K. Nishio, Y. Seki, A. Sarashina, M. Shahidi, N. Yamamoto
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Zhi-Qiang Ning, Zhi-Bin Li, Michael J. Newman, Song Shan, Xin-Hao Wang, De-Si Pan, Jin Zhang, Mei Dong, Xin Du, Xian-Ping Lu
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model
Yanping Luo, Fang Jiang, Todd B. Cole, Vincent P. Hradil, David Reuter, Arunava Chakravartty, Daniel H. Albert, Steven K. Davidsen, Bryan F. Cox, Evelyn M. McKeegan, Gerard B. Fox
Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients
Katsuya Nakai, Hiroyuki Mitomi, Yimit Alkam, Atsushi Arakawa, Takashi Yao, Emi Tokuda, Mitsue Saito, Fujio Kasumi
Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation
Roberto César P. Lima-Júnior, Aline A. Figueiredo, Helano C. Freitas, Maria Luisa P. Melo, Deysi Viviana T. Wong, Caio Abner V. G. Leite, Raul P. Medeiros, Raphael D. Marques-Neto, Mariana L. Vale, Gerly Anne C. Brito, Reinaldo B. Oriá, Marcellus H. L. P. Souza, Fernando Q. Cunha, Ronaldo A. Ribeiro
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates
Jodi A. Muscal, Yongkai Sun, Jed G. Nuchtern, Robert C. Dauser, Leticia H. McGuffey, Brian W. Gibson, Stacey L. Berg
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
Taroh Satoh, Yasushi Omuro, Yasutsuna Sasaki, Yasuo Hamamoto, Narikazu Boku, Takao Tamura, Atsushi Ohtsu
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
Chigusa Morizane, Takuji Okusaka, Hideki Ueno, Shunsuke Kondo, Masafumi Ikeda, Junji Furuse, Ohkawa Shinichi, Kohei Nakachi, Shuichi Mitsunaga, Yasushi Kojima, Eiichiro Suzuki, Makoto Ueno, Tomohiro Yamaguchi
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells
Vidya Mamidipudi, Tao Shi, Helen Brady, Sekhar Surapaneni, Rajesh Chopra, Sharon L. Aukerman, Carla Heise, Victoria Sung
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
C. Cauchi, N. Somaiah, P. F. Engstrom, S. Litwin, M. Lopez, J. Lee, M. Davey, B. Bove, M. von Mehren
Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation
Andrea Elio Sprio, Federica Di Scipio, Paolo Ceppi, Paolina Salamone, Francesco Di Carlo, Giorgio Vittorio Scagliotti, Mauro Papotti, Adriano Ceccarelli, Giovanni Nicolao Berta
The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers
Carlo L. Bello, Robert R. LaBadie, Grace Ni, Tanya Boutros, Carol McCormick, M. Noella Ndongo
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients
Naoto Takahashi, Masatomo Miura, Takenori Niioka, Kenichi Sawada
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer
M. Wada, M. Yamamoto, S. Ryuge, Y. Nagashima, N. Hayashi, S. Maki, S. Otani, K. Katono, A. Takakura, T. Yanaihara, S. Igawa, M. Yokoba, H. Mitsufuji, M. Kubota, M. Katagiri, N. Masuda
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Sukhmani K. Padda, Yelena Krupitskaya, Laveena Chhatwani, George A. Fisher, Alexander D. Colevas, Melanie San Pedro-Salcedo, Rodney Decker, Jane E. Latz, Heather A. Wakelee
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study
Steven G. DuBois, Suzanne Shusterman, Joel M. Reid, Ashish M. Ingle, Charlotte H. Ahern, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Peter C. Adamson, Susan M. Blaney
CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice
Ke-Ling Pei, Yi Yuan, San-Hai Qin, Yan Wang, Ling Zhou, Hou-Li Zhang, Xian-Jun Qu, Shu-Xiang Cui
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423
Robert T. Dorr, Lee Wisner, Betty K. Samulitis, Terry H. Landowski, William A. Remers
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
Peter Stopfer, Kristell Marzin, Hans Narjes, Dietmar Gansser, Mehdi Shahidi, Martina Uttereuther-Fischer, Thomas Ebner
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
Amrita V. Kamath, Dan Lu, Priyanka Gupta, Denise Jin, Hong Xiang, Anne Wong, Cecilia Leddy, Lisa Crocker, Gabriele Schaefer, Mark X. Sliwkowski, Lisa A. Damico-Beyer
Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
Amrita V. Kamath, Dan Lu, Priyanka Gupta, Denise Jin, Yan Xin, Ann Brady, Jean-Philippe Stephan, Hao Li, Janet Tien, Jing Qing, Lisa A. Damico-Beyer
Gene therapy with RNAi targeting UHRF1 driven by tumor-specific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo
Lin Fang, Li Shanqu, Gao Ping, He Ting, Wang Xi, Dong Ke, Long Min, Wei Junxia, Zhang Huizhong
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer, Michael J. Morris, Dana Rathkopf, Susan F. Slovin, Macaulay Steers, Steven M. Larson, Lawrence H. Schwartz, Tracy Curley, Anthony DeLaCruz, Qing Ye, Glenn Heller, Merrill J. Egorin, S. Percy Ivy, Neal Rosen, Howard I. Scher, David B. Solit
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
Yoshitaka Seki, Noboru Yamamoto, Yosuke Tamura, Yasushi Goto, Takashi Shibata, Maki Tanioka, Hajime Asahina, Hiroshi Nokihara, Yasuhide Yamada, Takashi Shimamoto, Kazuo Noguchi, Tomohide Tamura
Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity
Shousong Cao, Farukh A. Durrani, Youcef M. Rustum, Y. Eugene Yu